Description
Tirzepatide, the active compound in Mounjaro, acts as both a glucagon-like peptide-1 receptor agonist (GLP-1) and a glucose-dependent insulinotropic polypeptide receptor (GIP) agonist. Mounjaro, created by Eli Lilly and Company, is a clear to slightly yellow, preservative-free solution designed for subcutaneous injection. It’s available in pre-filled pens with solutions ranging from 2.5 mg to 15 mg for adults with type 2 diabetes mellitus to help manage blood sugar levels alongside diet and exercise.
Reviews
There are no reviews yet.